Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Michigan
Age
18–60
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Provide signed and dated informed consent form
Male or female, aged 18 to 60
Willing to comply with all study procedures and be available for the duration of the study
Primary diagnosis of schizophrenia or schizoaffective disorder according to DSM-IV (29)
Currently reporting AHs, rated a minimum of 4 (moderate) on the auditory hallucination item of the Brief Psychiatric Rating Scale (BPRS; 27), and AH will be present daily
AHs must have failed to resolve after a minimum of two adequate trials (doses within standard therapeutic range for a minimum of 8 weeks each) of psychotropic medication including at least one atypical antipsychotic medication; documented trials of antipsychotic medication limited by intolerable side effects, e. g. extra-pyramidal symptoms, tardive dyskinesia, weight gain, neuroleptic-induced dysphoria, will also be considered as equivalent to adequate trials.
Weight and girth compatible with the bore of the MRI scanner; generally men over 6 feet tall \< 250 lbs, men under 6 feet tall \< 220 lbs, women over 5'11" tall \< 220 lbs, or women under 5'10" tall \< 200 lbs
You may not be if
Substance abuse or dependence in the past 1 month
Current or past history of serious medical or neurological illness that could compromise brain function or present an increased risk of seizure, e. g. conditions that may significantly alter electrolyte balance, stroke, epilepsy, any history of seizure;
Pregnant or trying to become pregnant;
Inability to tolerate small, enclosed spaces without anxiety;
Metals, implants or metallic substances within or on the body that might cause adverse effects to the subject in a strong magnetic field, or interfere with image acquisition, e. g. aneurysm clips, retained particles, neurostimulators, foil-backed transdermal patches;
Facial tattoos with metallic ink
Inability to follow study protocol
Change in antipsychotic therapy in previous 2 weeks
Currently under an alternative treatment order
Unstable symptoms which could, in the judgment of the study team, exhibit symptomatic worsening over the course of the protocol
Current treatment with another investigational drug or other intervention
Anything that, in the opinion of the investigator, would place the subject at increased risk or preclude the subject's full compliance with or completion of the study;
No quantifiable motor threshold such that TMS dosage cannot be accurately determined
